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Background: Targeted screening of patients at high risk for methicillin-resistant Staphylococcus aureus (MRSA)
carriage is an important component of MRSA control programs, which rely on prediction tools to identify those
high-risk patients. Most previous risk studies reported a substantial rate of patients who are eligible for screening,
but failed to be enrolled. The characteristics of these missed patients are seldom described. We aimed to determine
the rate and characteristics of patients who were missed by a MRSA screening programme at our institution to see
how the failure to include these patients might impact the accuracy of clinical prediction tools.
Findings: From March-June 2010 all patients admitted to 13 internal medicine wards at the University of Geneva
Hospital (HUG) were prospectively screened for MRSA carriage. Of 1968 patients admitted to the ward, 267 patients
(13.6%) failed to undergo appropriate MRSA screening. Forty-one (2.4%) screened patients were MRSA carriers at
admission. On multivariate regression, patients who were missed by screening were more likely to be aged < 50 years
(OR 2.4 [1.4-3.9]), transferred to internal medicine from another ward in the hospital (OR 2.8 [1.1-7.1]), and have a history
of malignancy (OR 3.2[2.1-5.1]). There was no significant difference in the rate of previous MRSA carriage between
screened and unscreened patients.
Conclusions: Our findings highlight the potential bias that “missed” patients may introduce into MRSA risk scores.
Reporting on the proportions and characteristics of missed patients is essential for accurate interpretation of MRSA
prediction tools.
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Introduction
Prevention and control of MRSA cross infection is among
the most important challenges of infection control. Sur-
veillance of all patients for MRSA carriage on admission
to hospital allows those patients colonised with MRSA to
be isolated and contact precautions undertaken, with the
aim of minimising spread to other patients. As patients
with MRSA evident on routine clinical specimens repre-
sents a small fraction of the burden of MRSA, surveillance
is needed to identify the reservoir of colonised but not
infected patients [1,2]. However, universal surveillance uti-
lises significant healthcare resources, and its effectiveness* Correspondence: stephan.harbarth@hcuge.ch
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reproduction in any medium, provided the oris debatable [3-5]. Despite this, screening is increasingly
utilised in hospital MRSA control programs, and is still
legislated in the United Kingdom and some states of the
USA [6,7]. To mitigate costs without sacrificing the effect-
iveness of surveillance, many MRSA screening programs
rely on clinical prediction tools to target patients at high
risk of MRSA carriage [5]. Several epidemiological studies
form the basis of these tools in which the major risk fac-
tors for MRSA carriage have been identified, including: a
history of MRSA colonization, admission to intensive care,
hospitalization in the previous 12 months, extensive con-
tact with health care, previous receipt of antibiotic therapy
and skin or soft tissue infection at admission [8-12]. How-
ever, these studies report 5-83% of patients who were eli-
gible for study, but not screened. The characteristics of
these missed patients are seldom described [11]. We ex-
amined the characteristics of patients who were missedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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certain whether their exclusion might introduce bias and
affect the accuracy of clinical prediction tools and risk
profiling. Specifically, we hypothesised that an important
proportion of patients would be missed by our MRSA
screening programme, and that these patients would differ
from those patients who were not missed.Setting and methods
The University of Geneva Hospitals (HUG) are a 2200-
bed tertiary hospital network providing in- and outpatient
care to the Canton of Geneva. From March to June 2010 a
universal MRSA surveillance program was undertaken to
prospectively screen all patients consecutively admitted to
13 internal medicine wards. The primary aim of this study
was to determine the rate of MRSA carriage amongst pa-
tients admitted to internal medicine. Secondary aims in-
cluded: to formulate a clinical prediction tool that would
accurately predict those patients at high risk of MRSA car-
riage on admission to internal medicine, and to: determine
the effectiveness of our programme to capture all patients
for screening. Over the study period, all patient admissions
to internal medicine were recorded and basic demo-
graphic and clinical data was collected. Further clinical
data were obtained by retrospectively accessing electronic
medical records. All patients >18 years of age were eligible
for screening and were screened for MRSA by pooled nose
and groin swabs. Trained ward nurses conducted the
screening seven days a week. Pooled samples were streaked
onto MRSAid agar (bioMérieux, Lyon, France) and then in-
oculated into a colistin-salt (CS) broth. When no MRSA
was detected on chromogenic agar at day 1, a second
MRSAid plate was inoculated using the overnight enrich-
ment in the CS broth. Suspect colonies were confirmed by
a duplex polymerase chain reaction to assess the presence
of the mecA gene [13].
The proportion of patients who were eligible for, but did
not have MRSA screening was determined. Wilcoxon rank
sum tests and chi2-tests were used to assess differences
between screened and unscreened groups. Factors poten-
tially associated with failure to screen were first evaluated
using univariate logistic regression. Variables with a
P value <0.2 were retained. Multivariate models were then
developed and variables were eliminated in a stepwise
fashion using likelihood ratio tests to compare each model
to the previous one (STATA 11.2; StataCorp, College
Station, Texas, USA).Results
Of 1968 patients admitted to internal medicine, 1740
(88.4%) underwent admission screening within 48 hours
of admission. 228 (11.6%) admitted patients were notscreened and 39 (2.0%) patients underwent screening
but not within 48 hours of admission. Therefore, 267 pa-
tients (13.6%) failed to undergo appropriate MRSA screen-
ing. Forty-one (2.4%) screened patients were MRSA
carriers at admission. Patients who were missed during
MRSA screening were younger (57.1 years vs 61.6 years;
P < 0.0001) and a greater percentage had been transferred
to internal medicine from another hospital ward (7.0% vs
2.7%; P < 0.0001). The proportions of patients identified as
previous MRSA carriers was not significantly different be-
tween the screened and unscreened groups (9.6% vs
13.2%, respectively, P = 0.308). There was no significant
difference in the proportion of patients missed by screen-
ing on weekends as compared to weekdays. The results of
uni- and multivariate regression analysis of factors poten-
tially associated with being missed for MRSA screening
are shown in the Table 1. On multivariate regression,
patients who were missed by screening were more likely
to be aged < 50 years, admitted to internal medicine from
another hospital, and have a history of malignancy.Discussion
Screening patients for MRSA carriage on admission to
hospital is an increasingly important component of hos-
pital MRSA control programs. Many programs rely on
prediction tools so that patients at high risk of MRSA car-
riage may be targeted for selective screening rather than
to utilise universal screening which is costly and resource
intensive. Ideally, prediction tools are formulated using
local epidemiological data from (universal) surveillance
studies. However, many of these studies report a substan-
tial rate of patients who are eligible for screening, but fail
to be enrolled by the surveillance programme. The charac-
teristics of these patients are seldom described.
In this study, 13.6% of patients failed to have admission
MRSA screening swabs performed. This rate of “missed”
screening opportunities is comparable to that found in
other MRSA risk profiling studies [8-11,14]. Patients who
were not screened differed from those who were in several
ways. Firstly, younger patients (<50 years) were more likely
to be missed during MRSA screening. A possible explan-
ation for this is that nurses perceived younger patients to
be at low risk for MRSA carriage and were thus less in-
clined to pursue screening. Although older age is fre-
quently identified as a risk factor for MRSA carriage
[8,10,12], it is possible that the tendency to miss younger
patients from screening may contribute to this finding and
inflate effect estimates. Transfer to internal medicine from
another hospital department (intra-hospital transfer) was
also a risk factor for being missed during screening. Intra-
hospital transfer has been previously identified as a risk
factor for MRSA admission carriage [10]; missing this
group of patients could result in an underestimation of
Table 1 Results of uni- and multi-variate regression analyses of factors associated with failure to have an admission
MRSA swab performed1
Proportions (n) Univariate regression Multivariate regression
Variable Swabs missed (n = 267) Swabs done (n = 1740) OR [95%CI] P value Adjusted OR [95%CI] P value
Male sex 55.9 (148) 58.6 (997) 0.9 [0.7-1.1] 0.402
Age < 50 years old 30.3 (81) 19.9 (339) 1.7 [1.3-2.3] <0.001 2.4 [1.4-3.9] <0.001
Admitted from ICU 4.5(12) 7.6(129) 0.6 [0.3-1.1] 0.074
Admitted from another ward 7.1(19) 2.7(45) 2.8 [1.6-4.9] <0.001 2.8 [1.1-7.1] 0.028
Admitted from home 88.3(235) 89.7(1526) 0.9 [0.6-1.3] 0.484
Uncomplicated diabetes mellitus 10.4(12 18.7(126) 0.5 [0.3-0.9] 0.034
Acute renal failure 10.4(12 21.8(147) 0.4 [0.2-0.8] 0.006
Chronic renal failure 6.1(7) 13.8(93) 0.4 [0.2-0.9] 0.026
End stage renal failure 4.3(5) 2.4(16) 1.9 [0.7-5.2] 0.231
Complicated diabetes mellitus 5.2(6) 9.8(66) 0.5 [0.2-1.2] 0.122
Peripheral vascular disease 2.6(3) 4.3(29) 0.6 [0.2-2.0] 0.400
Chronic obstructive pulmonary disease 9.6(11) 14.4(97) 0.6 [0.3-1.2] 0.167
Dementia 0.9(1) 1.5(10) 0.6 [0.07-4.6] 0.608
Stroke 0 0.9(6) Omitted
Cerebral haemorrhage 1.0(1) 0.4(3) 2.0 [0.2-19.0] 0.561
Congestive cardiac failure 11.3(13) 24.8(167) 0.4 [0.2-0.7] 0.002
Ischaemic heart disease 10.4(12) 11.3(76) 0.9 [0.5-1.8] 0.791
Haematological malignancy 10.4(12) 5.8(39) 1.9 [1.0-3.7] 0.065
Carotid artery stenosis 0 1.2(8) Omitted
Parkinsons disease 0.9(1) 0.7(5) 1.2 [0.1-10.2] 0.884
Connective tissue disease 0.9(1) 2.2(15) 0.4 [0.05-2.9] 0.358
Liver failure 1.0(1) 1.8(12) 0.5 [0.06-3.8] 0.488
Respiratory failure 0 1.0(7) Omitted
Solid organ cancer 35.7(41) 15.4(104) 3.0 [1.9-4.7] <0.001 3.2[2.1-5.1] <0.001
Metastatic cancer 12.6(13) 7.3(50) 1.8 [0.3-3.9] 0.866 2.6 [1.4-4.8] 0.004
Peptic ulcer disease 1.9(2) 2.5(17) 1.1 [0.3-3.9] 0.866
Infection 1.9(2) 0.7(5) 2.4 [0.5-12.5] 0.301
Day of the week
Monday 8.90(35) 91.10(358) 0.8[0.4-1.4] 0.355
Tuesday 16.02(62) 83.98(325) 1.5[0.9-2.5] 0.140
Wednesday 15.93(54) 84.07(285) 1.5[0.9-2.5] 0.155
Thursday 16.08(46) 83.92(240) 1.5[0.9-2.6] 0.153
Friday 15.49(35) 84.51(191) 1.4[0.8-2.6] 0.226
Saturday 8.61(13) 91.39(138) 0.7[0.4-1.5] 0.408
Sunday 11.35(21) 88.65(164) 0.8[0.5-1.3] 0.365
1. Denominators used to calculate proportions were adjusted for the number of patients in whom data were available. OR odds ratio, CI confidence interval.
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intra-hospital transfer as an important risk factor for
MRSA carriage. Patients with malignancy were more likely
to be missed during screening in our study. This was due
to logistic difficulties (e.g. frequent readmissions for
chemotherapy; ultra-short hospitalizations) within our
hospital oncology ward that impeded their regularparticipation in screening, and was therefore a problem
specific to our institution.
To our knowledge, the study by Furano et al. is the
only one to report detailed characteristics of patients
missed by MRSA screening [11]. In this study, 83.7% of
eligible patients were not enrolled in screening. Un-
enrolled patients were older, less likely to have had a
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in-hospital mortality than those patients who were en-
rolled [11]. The present study will help to further eluci-
date the importance and magnitude of misclassification
bias in MRSA risk profiling studies.
Our study has several limitations. Firstly, it is likely that
the effectiveness of hospital surveillance programmes to
enrol patients on admission may be heavily influenced by
institutional and local factors. Therefore, the generalizability
of our findings may be limited. Secondly, some of our data
was collected retrospectively from medical records and is
therefore subject to the inaccuracies inherent to data col-
lected in this way.
Nevertheless, we believe that our findings highlight
some of the potential misclassification biases that may
occur in MRSA risk profiling studies due to patients
missed from screening. This could have important impli-
cations for the accuracy of MRSA risk scores developed
to target MRSA screening. Clear reporting on patient re-
cruitment and the proportions and characteristics of
those patients missed is essential for accurate interpret-
ation of clinical prediction tools identifying patients at
high risk for carriage of antibiotic-resistant bacteria.
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